Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guerin-naive High-risk Nonmuscle-invasive Bladder Cancer

被引：0
|
作者：
Kavoussi, Mehraban [1 ]
Nasrallah, Ali A. [1 ]
Williams, Stephen B. [1 ]
机构：
[1] Univ Texas Med Branch, Div Urol, Galveston, TX USA
来源：
EUROPEAN UROLOGY | 2022年 / 82卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1016/j.eururo.2022.08.024
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：659 / 659
页数：1
相关论文
共 50 条
  • [1] Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guerin-Naive High-Risk Nonmuscle-Invasive Bladder Cancer
    McElree, Ian M.
    Steinberg, Ryan L.
    Martin, Alex C.
    Richards, Jordan
    Mott, Sarah L.
    Gellhaus, Paul T.
    Nepple, Kenneth G.
    O'Donnell, Michael A.
    Packiam, Vignesh T.
    JOURNAL OF UROLOGY, 2022, 208 (03): : 589 - 597
  • [2] Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guerin-Naive High-Risk Nonmuscle-Invasive Bladder Cancer REPLY
    不详
    JOURNAL OF UROLOGY, 2022, 208 (03): : 599 - 599
  • [3] Sequential intravesical gemcitabine and docetaxel for BCG-naive high-risk nonmuscle-invasive bladder cancer.
    McElree, Ian Mitchell
    Steinberg, Ryan L.
    Mott, Sarah L.
    Martin, Alexander C.
    Richards, Jordan
    Gellhaus, Paul T.
    Nepple, Kenneth G.
    O'Donnell, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [4] Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure
    Sternberg, Itay A.
    Dalbagni, Guido
    Chen, Ling Y.
    Donat, Sherri M.
    Bochner, Bernard H.
    Herr, Harry W.
    JOURNAL OF UROLOGY, 2013, 190 (05): : 1686 - 1691
  • [5] Maintenance bacillus Calmette-Guerin in high-risk nonmuscle-invasive bladder cancer - How much is enough?
    Decobert, Marc
    LaRue, Helene
    Harel, Francois
    Meyer, Francois
    Fradet, Yves
    Lacombe, Louis
    CANCER, 2008, 113 (04) : 710 - 716
  • [6] Sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guerin for the treatment of high-risk, treatment-naive, non-muscle invasive bladder cancer.
    McElree, Ian M.
    Steinberg, Ryan L.
    Mott, Sarah L.
    O'Donnell, Michael A.
    Packiam, Vignesh T.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Guerin Downregulation of Nonmuscle-invasive Bladder Cancer
    Camargo, Juliana A.
    Passos, Gabriela R.
    Ferrari, Karen L.
    Billis, Athanase
    Saad, Mario J. A.
    Reis, Leonardo O.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (03) : E587 - E593
  • [8] Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guerin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer
    McElree, Ian M.
    Steinberg, Ryan L.
    Mott, Sarah L.
    O'Donnell, Michael A.
    Packiam, Vignesh T.
    JAMA NETWORK OPEN, 2023, 6 (02) : e230849
  • [9] Adding mitomycin to Bacillus Calmette-Guerin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301)
    Liow, Elizabeth Chien Hern
    Hayne, Dickon
    Stockler, Martin R.
    Martin, Andrew James
    Sengupta, Shomik
    Anderson, Paul
    Ford, Kate
    Frydenberg, Mark
    Gorzeman, Margot
    Green, Will
    Grummet, Jeremy
    Hawks, Cynthia
    Krieger, Laurence Eliot Miles
    Ischia, Joseph
    McCombie, Steve
    Patel, Manish
    Davis, Ian D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [10] Nonrisk-adapted Sequential Intravesical Gemcitabine and Docetaxel for Nonmuscle-invasive Bladder Cancer: The Time Is Now
    Steinberg, Ryan L.
    O'Donnell, Michael A.
    Packiam, Vignesh T.
    JOURNAL OF UROLOGY, 2023, 210 (01): : 5 - 7
12345